Seeking Alpha
Profile| Send Message|
( followers)  

Spectrum Pharmaceuticals (Nasdaq: SPPI) has two upcoming dates with regulators in the coming months.

  • July 2: Zevalin
  • October 8: Fusilev
Bayer Schering (Bayer) markets Zevalin in Europe and abroad - all countries ex. US. Bayer received approval for Zevalin as a first-line consolidation therapy on April 28, 2008. For details, please refer to my June 28 article.
Here are 17 good reasons why Bayer might seriously consider acquiring Spectrum Pharmaceuticals at some point in the future. Listed below are 17 ongoing clinical trials for Zevalin. Each trial is sorted by its corresponding completion date. Data source: FDA.
2009

August
Phase 2
Fludarabine Plus . . .
September
Phase 2
Response Study of Zevalin in Patients with DLBCL after 6 cycles of CHOP.
December
Phase 3
Study Comparing Zevalin Regimen with NO FURTHER TREATMENT in DLBCL
Patients who are in Complete Remission after CHOP-R

2010

January
Phase 2
Zevalin in Combination with Z-CHOP in Treating Patients with Stage 2-4 DLBCL.
July
Phase 2
Zevalin + Rituxan Maintenance, University of Wisconsin
August
Phase 2
Autologous Stem Cell Transplant with Zevalin + Busulfan
December
Phase 2
Chemo followed by Zevalin for Relapsed Mantle Cell Lymphoma,
Dana-Faber Cancer Institute

2011

January
Phase 2
Safety of Zevalin,
Sponsor: Bayer Schering

2012

January
Phase 2
ZEVALIN TWICE IN AGGRESSIVE NHL
January
Phase 2
Safety Study to Evaluate Induction & Consolidation Treatment in Mantle Cell Lymphoma
June
Phase 3
Zevalin-BEAM for aggressive lymphoma
Sponsor: Sheba Medical Center
December
Phase 1 / 2
Zevalin with Non Myeloablative Allogeneic Stem Cell Transplant in NHL

2013

April
Phase 2
Consolidation Treatment with Zevalin after R-CHOP Induction in High Risk Patients According to FLIPI with fNHL.

2014

June
Phase 2
Zevalin-BEAM with Autologous Stem Cell
August
Phase 2
Zevalin & Simultaneous Application of BEAM High Dose Chemo
October
Phase 2
Zevalin First-Line fNHL
Sponsor: Charite University, Berlin, Germany

2016

December
Phase 2
R-CHOP in fNHL Patients NOT Previously Treated. Consolidation with Zevalin
versus Maintenance with Rituxan

Conclusion

Though it is NOT possible to conclude that Bayer will acquire SPPI with any certainty, it does, however, seem plausible.
Disclosure: Long SPPI
Source: 17 Reasons Why Bayer Might Acquire Spectrum Pharmaceuticals